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The inhibitory effects of the 9-(2-phosphonylmethoxyethyl)adenine-related compounds (S)-9-(3-hydroxy-2-
phosphonylmethoxypropyl)-adenine, (S)-9-(3-fluoro-2-phosphonylmethoxypropyl)adenine, (R)-9-(2-phospho-
nylmethoxypropyl)adenine, (R)-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine, and (S)-1-(3-hydroxy-2-
phosphonylmethoxypropyl)cytosine on human hepatitis B virus replication in the human hepatoma cell line
HepG2 2.2.15 and duck hepatitis B virus infection in primary duck hepatocytes were investigated. (R)-9-(2-
phosphonylmethoxypropyl-2,6-diaminopurine had the lowest 50%o inhibitory concentrations against hepatitis B
virus and duck hepatitis B virus, 0.22 and 0.06 ,iM, respectively, i.e., two- to fivefold lower concentrations than
required for (R)-9-(2-phosphonylmethoxypropyl)adenine and 9-(2-phosphonylmethoxyethyl)adenine. All com-
pounds were not toxic in vitro at a concentration of 100 ,uM.
In chronic hepatitis B virus (HBV) infection the basic therapy
is the administration of interferon, although complete disappear-
ance of virus markers is seldom observed. Hepatitis B e antigen
seroconversion, reflecting a drastic decline of viral replication,
is seen in only 20 to 40% of patients with HBV infections.
More potent antiviral drugs are eagerly awaited, and in light
of this, the acyclic nucleoside phosphonates described earlier
(3, 4) were considered adequate candidates to be further
pursued for the treatment of HBV infections.
In an earlier study (6) we investigated the acyclic nucleoside
phosphonate 9-(2-phosphonylmethoxyethyl)adenine (PMEA)
in two hepatoma cell lines and primary duck hepatocytes. The
50% inhibitory concentrations (IC50) for human HBV and
duck HBV (DHBV) were found to be 1.2 and 0.2 ,uM as
measured in HepG2 2.2.15 cells and primary duck hepatocytes,
respectively.
Among the acyclic nucleoside phosphonates several other
derivatives were found to have high anti-DNA virus activity
(herpes group) or antiretrovirus (human immunodeficiency
virus [HIV] and Moloney murine sarcoma virus) activity (1).
The most effective HIV inhibitors among the acyclic nucleo-
side phosphonates were evaluated for their anti-HBV activities
in the human hepatoma cell line HepG2 2.2.15. Two of the
compounds, candidates for application with humans, were also
assayed in primary duck hepatocytes infected with DHBV, in
anticipation of studies with chronically DHBV-infected duck-
lings and chronic hepatitis B patients.
PMEA, (S)-9-(3-fluoro-2-phosphonylmethoxypropyl)adenine
[(S)-FPMPA], (R)-9-(2-phosphonylmethoxypropyl)-2,6-diami-
nopurine [(R)-PMPDAP], (S)-9-(3-hydroxy-2-phosphonyl-
methoxypropyl)adenine [(S)-HPMPA], (R)-9-(2-phosphonyl-
methoxypropyl)adenine [(R)-PMPA], and (S)-9-(3-hydroxy-2-
phosphonylmethoxypropyl)cytosine were synthesized by A.
Holy, D. Dvorakova, and I. Rosenberg at the Institute of
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Organic Chemistry and Biochemistry, Academy of Sciences of
the Czech Republic, Prague, Czech Republic. The structures of
the test compounds are depicted in Fig. 1. The HepG2 2.2.15
hepatoblastoma cell line (8) was kindly donated by G. Acs
(Mount Sinai Medical Center, New York, N.Y.). Duck hepa-
tocytes were obtained from 2-week-old DHBV DNA-positive
ducklings by collagenase perfusion, as described previously (5).
The DHBV strain was kindly supplied by K. N. Tsiquaye
(London, United Kingdom). Experimental conditions of cell
culture for the human hepatoma cell line and the primary duck
hepatocytes were as described before (6). The culture medium
of HepG2 2.2.15 cells was changed at day 3 after seeding and
was supplemented with various concentrations of the drug.
The culture medium, including the drug, was changed subse-
quently every third day. For DHBV-infected duck hepatocytes,
the medium was changed at day 1 after seeding and subse-
quently every other day. From day 3 on, the medium was
supplemented with various concentrations of the drug. The
50% cytotoxic concentration was determined by inhibition of
6-[3H]thymidine ([6-3H]dThd) incorporation into HepG2
2.2.15 cell DNA and inhibition of HepG2 2.2.15 cell prolifer-
ation as described before (6). For analysis of extracellular
HBV DNA and DHBV DNA, cell culture supernatants
(HepG2 2.2.15 cells, day 12; duck hepatocytes, day 11), clari-
fied by centrifugation, were prepared for dot blot analysis
according to the method of Korba and Milman (7). HBV DNA
and DHBV DNA were applied to a Hybond N+ membrane
(Amersham Life Science Products) in the Convertible Filtra-
tion Manifold System (Bethesda Research Laboratories). Hy-
bridization of HBV DNA sequences was performed with a
[32P]dCTP-labelled EcoRI fragment of pCP10 containing the
full-length 3.2-kb genome of human HBV (2). For hybridiza-
tion of DHBV DNA sequences, a [32P]dClP-labelled EcoRI
fragment of the plasmid pBR322 containing the full-length
(3.0-kb) genome of DHBV was used. The plasmid was kindly
donated by H. E. Blum (Freiburg, Germany). Labelling reac-
tions were carried out with the Prime-a-Gene labelling system
(Promega). For the calculation of the IC50 from autoradio-
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FIG. 1. Structural formulae of the acyclic nucleoside phosphonate derivatives.
grams from dot spot hybridization, an LKB 222-020 Ultra Scan
XL laser densitometer was used.
Table 1 presents the results of the evaluation of two
3-hydroxy-2-phosphonylmethoxypropyl and three 2-phospho-
nylmethoxypropyl derivatives for their inhibitory effects on
Dane particle secretion by HepG2 2.2.15 cells. A relatively
high IC50 was found for (S)-9-(3-hydroxy-2-phosphonylme-
thoxypropyl)cytosine, a compound that is currently being
tested as a candidate antiviral drug for the treatment of
herpesvirus infections. In contrast, (S)-HPMPA proved to be
highly active against HBV in HepG2 2.2.15 cells and HB611
cells (9) and against DHBV in primary duck hepatocytes (10).
Comparable activity was found for PMEA, a compound known
to have both DNA virus and retrovirus inhibitory activities (1).
(R)-PMPA and (S)-FPMPA, two effective HIV inhibitors,
were also found to have potent inhibitory activities against
HBV. None of the compounds evaluated had a marked
inhibitory effect on HepG2 2.2.15 cell proliferation at 100 ,uM
(Table 1). No inhibition of [6-3H]dThd incorporation of
HepG2 2.2.15 cell DNA was noted at 100 p,M.
In the present study, (R)-PMPDAP emerged as the most
effective inhibitor of HBV in HepG2 2.2.15 cells. (R)-PMP
DAP has also emerged as the most effective HIV inhibitor
among a large series of acyclic nucleoside phosphonates (1).
TABLE 1. Inhibitory effects of acyclic nucleoside phosphonates on extracellular HBV and DHBV production, cell proliferation,
and [6-3H]dThd incorporation into DNA
HBV production, HepG2 DHBV production, primary duck HepG2 2.2.15 cells
2.2.15 cells hepatocytes
CompoundICamICuIn Cell growth, [6-3H]dThd incorporation
'C50 ico IC5 so9 cc5ob into DNA, IC50
PMEAC 1.2 ± 0.0 19 ± 13 0.14 ± 0.03 0.36 ± 0.01 >100 >100
(S)-HPMPA 1.5 >100 >100
(S)-HPMCd 14 >100 >100
(S)-FPMPA 1.2 >100 >100
(R)-PMPAc 1.5 ± 0.05 10 ± 2.8 0.11 ± 0.02 0.28 ± 0.02 >100 >100
(R)-PMPDAPc 0.22 ± 0.03 1.3 ± 0.36 0.06 ± 0.01 0.19 ± 0.01 >100 >100
a ICg, 90% inhibitory concentration.b CC50, 50% cytotoxic concentration.
c Data are the means from two independent experiments carried out in duplicate.
d (S)-HPMPC, (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine.
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Among the compounds [PMEA, (S)-HPMPA, (R)-PMPA, and
(S)-FPMPA] that showed comparable IC50 (Table 1), PMEA
is now in clinical trials for the treatment of HIV infections,
(S)-HPMPA appears from animal data to be too toxic for
clinical use, and (S)-FPMPA is rather expensive to produce.
Therefore, (R)-PMPDAP and (R)-PMPA were chosen as the
best candidates for further evaluation with duck hepatocytes.
As a control, we included PMEA.
In experiments using DHBV-infected duck hepatocytes,
IC50 of 0.06 and 0.11 ,uM were found for (R)-PMPDAP and
(R)-PMPA, respectively. For PMEA, an IC50 of 0.2 ,uM was
registered earlier (6). The lowest IC50 as well as the lowest
90% inhibitory concentration were found once more for
(R)-PMPDAP. In fact, the same order of antiviral potencies of
the test compounds was found in the HBV-infected HepG2
2.2.15 cell and DHBV-infected duck hepatocyte models. These
observations may point to the suitability of the DHBV model
for determining the relative activities of series of related
compounds in vitro.
The 50% cytotoxic concentration of (R)-PMPDAP and
(R)-PMPA was >100 ,uM for both HepG2 2.2.15 cells and
DHBV-infected duck hepatocytes (data not shown).
In summary, the high inhibitory effect of (R)-PMPDAP on
hepadnavirus infections in both HepG2 2.2.15 cells and
DHBV-infected duck hepatocytes is encouraging for further
studies with ducks and humans.
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